Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification.

Inhibition of the Chk1 kinase by small molecules binding to its active site is a strategy of great therapeutic interest for oncology. We report how computational modelling predicted the binding mode of ligands of special interest to the Chk1 ATP site, for representatives of an indazole series and debromohymenialdisine. These binding modes were subsequently confirmed by X-ray crystallography. The binding mode of a potent indazole derivative involves non-conventional C-H...O and N-H...pi-aromatic interactions with the protein. These interactions are formed in a buried pocket at the periphery of the ATP-binding site, the importance of which has previously been overlooked for ligand design against Chk1. It is demonstrated that filling this pocket can confer ligands with dramatically enhanced affinity for Chk1. Structural arguments in conjunction with assay data explain why targeting this pocket is also advantageous for selective binding to Chk1. Structural overlays of known inhibitors complexed with Chk1 show that only the indazole series utilizes the pocket of interest. Therefore, the analysis presented here should prove helpful in guiding future structure-based ligand design efforts against Chk1.

[1]  Yuzhu Chen,et al.  N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. , 2004, Journal of medicinal chemistry.

[2]  Susan S. Taylor,et al.  2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. , 1993, Acta crystallographica. Section D, Biological crystallography.

[3]  N. Rhind,et al.  Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast. , 1997, Genes & development.

[4]  L. Toledo,et al.  The structure-based design of ATP-site directed protein kinase inhibitors. , 1999, Current medicinal chemistry.

[5]  D. Schomburg,et al.  Prediction of protein three-dimensional structures in insertion and deletion regions: a procedure for searching data bases of representative protein fragments using geometric scoring criteria. , 1995, Journal of molecular biology.

[6]  S. Scheiner,et al.  Comparison of various types of hydrogen bonds involving aromatic amino acids. , 2002, Journal of the American Chemical Society.

[7]  D. Sutor.  The C–H… O Hydrogen Bond in Crystals , 1962, Nature.

[8]  J. Jackson,et al.  An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. , 2000, Cancer research.

[9]  P. Charifson,et al.  Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. , 2001, Journal of medicinal chemistry.

[10]  David E. Williams,et al.  Inhibition of the G2 DNA Damage Checkpoint and of Protein Kinases Chk1 and Chk2 by the Marine Sponge Alkaloid Debromohymenialdisine* , 2001, The Journal of Biological Chemistry.

[11]  H Boxenbaum,et al.  Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[12]  T. Halgren.  MMFF VI. MMFF94s option for energy minimization studies , 1999, J. Comput. Chem..

[13]  Sven Hellberg,et al.  Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418* , 2003, Journal of Biological Chemistry.

[14]  N. Rhind,et al.  Chk1 and Cds1: linchpins of the DNA damage and replication checkpoint pathways. , 2000, Journal of cell science.

[15]  Olga Kennard,et al.  Crystallographic evidence for the existence of CH.cntdot..cntdot..cntdot.O, CH.cntdot..cntdot..cntdot.N and CH.cntdot..cntdot..cntdot.Cl hydrogen bonds , 1982 .

[16]  T. Kawabe.  G2 checkpoint abrogators as anticancer drugs. , 2004, Molecular cancer therapeutics.

[17]  J A McCammon,et al.  Determinants of ligand binding to cAMP-dependent protein kinase. , 1999, Biochemistry.

[18]  G. Nichol,et al.  6-Methyl-2-pyridone pentahydrate , 2004 .

[19]  D. Toczyski,et al.  A unified view of the DNA-damage checkpoint. , 2002, Current opinion in cell biology.

[20]  Andrew Potter,et al.  Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity. , 2005, Journal of medicinal chemistry.

[21]  P. Russell,et al.  Serine-345 is required for Rad3-dependent phosphorylation and function of checkpoint kinase Chk1 in fission yeast , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[23]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[24]  A. Senderowicz.  The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. , 2002, The oncologist.

[25]  Gautam R. Desiraju,et al.  The Weak Hydrogen Bond: In Structural Chemistry and Biology , 1999 .

[26]  M. Nishio,et al.  The CH/π interaction: Significance in molecular recognition , 1995 .

[27]  H. Ohigashi,et al.  Indolactam-V Is Involved in the CH/π Interaction with Pro-11 of the PKCδ C1B Domain: Application for the Structural Optimization of the PKCδ Ligand , 2005 .

[28]  Dino Moras,et al.  C-H...O hydrogen bonds in the nuclear receptor RARgamma--a potential tool for drug selectivity. , 2002, Structure.

[29]  T. Steiner.  Donor and acceptor strengths in C–H···O hydrogen bonds quantified from crystallographic data of small solvent molecules , 1998 .

[30]  N. Rhind,et al.  Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. , 1997, Science.

[31]  X. Barril,et al.  Virtual screening in structure-based drug discovery. , 2004, Mini reviews in medicinal chemistry.

[32]  G. Bemis,et al.  Kinase inhibitors and the case for CH…O hydrogen bonds in protein–ligand binding , 2002, Proteins.

[33]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[34]  David Komander,et al.  High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site , 2002, The EMBO journal.

[35]  A. Eastman,et al.  The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. , 2003, Cancer research.

[36]  Gaoquan Li,et al.  1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. , 2005, Journal of medicinal chemistry.

[37]  J. Sühnel,et al.  C-h⋯π-interactions in proteins , 2001 .

[38]  Qun Li,et al.  Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. , 2002, Current topics in medicinal chemistry.

[39]  G. Desiraju,et al.  NH…O, OH…O, and CH…O hydrogen bonds in protein–ligand complexes: Strong and weak interactions in molecular recognition , 2003, Proteins.

[40]  S. Haggarty,et al.  High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. , 1998, Cancer research.

[41]  Eugene M. Fluder,et al.  Tautomerization of formamide, 2-pyridone, and 4-pyridone: an ab initio study , 1982 .

[42]  Edward A. Sausville,et al.  The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01* , 2000, The Journal of Biological Chemistry.

[43]  D. Poon,et al.  Isolation and Characterization of TAF25, an Essential Yeast Gene That Encodes an RNA Polymerase II-specific TATA-binding Protein-associated Factor* , 1996, The Journal of Biological Chemistry.

[44]  A. Davis,et al.  Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. , 1999, Angewandte Chemie.

[45]  T. Steiner,et al.  Hydrogen bonds with pi-acceptors in proteins: frequencies and role in stabilizing local 3D structures. , 2001, Journal of molecular biology.

[46]  R. Simmer,et al.  Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. , 2001, Neoplasia.

[47]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[48]  S. Elledge,et al.  Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.

[49]  Maria Jesus Martin,et al.  High-quality Protein Knowledge Resource: SWISS-PROT and TrEMBL , 2002, Briefings Bioinform..

[50]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[51]  A. Lesk,et al.  The relation between the divergence of sequence and structure in proteins. , 1986, The EMBO journal.

[52]  D. Morgan,et al.  Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells , 1996, The Journal of cell biology.

[53]  Steve Scheiner,et al.  Fundamental Properties of the CH···O Interaction: Is It a True Hydrogen Bond? , 1999 .

[54]  M. Levitt,et al.  Aromatic Rings Act as Hydrogen Bond Acceptors , 2022 .

[55]  K. Kohn,et al.  Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.

[56]  Anastassis Perrakis,et al.  Automated protein model building combined with iterative structure refinement , 1999, Nature Structural Biology.

[57]  M. Mayersohn,et al.  Evaluation of a minimal experimental design for determination of enzyme kinetic parameters and inhibition mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.

[58]  F. Diederich,et al.  Interactions with aromatic rings in chemical and biological recognition. , 2003, Angewandte Chemie.

[59]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[60]  Brian A. Hemmings,et al.  Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP , 2002, Nature Structural Biology.

[61]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[62]  Andreina Santagostino,et al.  A User-Friendly Entry to 2-Iodoxybenzoic Acid (IBX) , 1999 .

[63]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[64]  T. Hunter,et al.  Cyclin-dependent Kinases Are Inactivated by a Combination of p21 and Thr-14/Tyr-15 Phosphorylation after UV-induced DNA Damage* , 1996, The Journal of Biological Chemistry.

[65]  W. Brownell,et al.  Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.

[66]  A. Fersht.  The hydrogen bond in molecular recognition , 1987 .

[67]  E. Sausville,et al.  Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  G. Zachos,et al.  Chk1‐deficient tumour cells are viable but exhibit multiple checkpoint and survival defects , 2003, The EMBO journal.

[69]  M. Levitt.  Accurate modeling of protein conformation by automatic segment matching. , 1992, Journal of molecular biology.

[70]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[71]  David H. Williams,et al.  Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. , 2002, Current opinion in pharmacology.

[72]  S. David Morley,et al.  Validation of an empirical RNA-ligand scoring function for fast flexible docking using RiboDock® , 2004, J. Comput. Aided Mol. Des..

[73]  J. Dunitz.  The entropic cost of bound water in crystals and biomolecules. , 1994, Science.